BNET Industries
Market Cap:$1.4B
Last Fiscal Year Sales:$345.3M
- Public
- US
Dow Jones Description
Abraxis BioScience is a fully integrated biotechnology company dedicated to delivering progressive therapeutics, such as ABRAXANE, and core technologies that offer patients and medical professionals safer and more effective treatments for cancer and other critical illnesses. Abraxis' portfolio includes the world's first and only protein-based nanoparticle chemotherapeutic compound. Scientists at Abraxis developed its proprietary tumor targeting system known as the nab Technology platform, an innovative approach to treating cancer and other critical illnesses. By harnessing the unique natural properties of the human protein albumin, Abraxis' nab technology platform enables the transport and delivery of therapeutic agents to the site of disease. This revolutionary biologically interactive delivery system is being further developed with other water insoluble drugs for their potential use across a broad range of tumors. ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound), the first U.S. Food and Drug Administration (FDA) approved product to use the nab platform, was launched in 2005 for the treatment of metastatic breast cancer. From the discovery and research phase to development and commercialization, Abraxis BioScience is committed to rapidly enriching the company's pipeline and accelerating the delivery of breakthrough therapies that will transform the lives of the patients who need them. ...
Vice Chairman, President & CEO
Leon O. MoulderNumber of Employees 734
Contact Information
11755 Wilshire Blvd Ste 2000
Los Angeles, California 90025
(310) 883-1300
Peer Companies
NAICS Code Medical Laboratories: 621511
Recent Events
-
Abraxis BioScience Reports 2009 Third Quarter Financial Results
-
Abraxis BioScience Names Rick Rodgers Succeeding David O'Toole As CFO - Update
-
BRIEF-Abraxis Bioscience names Rick Rodgers chief financial officer
-
Market Report -- In Play ABII
-
Abraxis BioScience Appoints CFO
News & Analysis
Filter by
abraxis bioscience inc. - All News and Analysis
Abraxis BioScience, Inc., Q4 2008 Earnings Call Transcript
Question-and-Answer SessionOperator Operator Instructions. And your first question comes from the line of Claude Camire, of Paradigm Capital. Please proceed. Claude Camire - Paradigm Capital Hi, good morning. I wanted to find out what would be the expected time for in Japan for ABRAXANE? Patrick Soon-Shiong...
Abraxis Biosciences, Inc., Q2 2008 Earnings Call Transcript
Question-and-Answer SessionOperator Operator Instructions At this time there are no questions. Patrick Soon-Shiong Well, thank you all for joining us this morning to discuss our 2008 second quarter results. So, if anybody has any other questions, please feel free to contact our Investor Relations team at Abraxis. And this...
Abraxis Bioscience, Inc. Q1 2008 Earnings Call Transcript
Earnings Call ExcerptAbraxis Bioscience, Inc. ABII Q1 2008 Earnings Call May 15, 2008 11:30 am ET Executives Daniel Saks – Vice President of Investor Relations and Corporate Communication Patrick Soon-Shiong, M.D. – Chairman and Chief Executive Officer Lisa Gopalakrishna – Chief Financial Officer Presentation Operator Good day ladies...
Abraxis BioScience, Inc. Q3 2007 Earnings Call Transcript
Question-and-Answer Session Operator : [Operators Instructions]. Your first question comes from the line of Elliot Wilbur with CIBC World Markets. Please proceed. Elliot Wilbur - CIBC World Markets : Thanks, good morning. First quick question for Lisa with respect...
Abraxis BioScience and the California NanoSystems Institute Announce Partnership for Collaborative Research in the Development of New Nanobiotechnologies
LOS ANGELES -- Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, and the California NanoSystems Institute at UCLA today announced a partnership designed to collaborate on early research in nanobiotechnology for the advancement of new technologies in medicine. Abraxis BioScience will collaborate with the CNSI and its team...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Thomas H. Silberg | President and Chief Executive Officer |
| David D. O. Toole | Executive Vice President and Chief Financial Officer |
| David O'Toole | CFO & Executive Vice President |
| David O. Toole | Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) |
| Mary Lynne Hedley | Executive Vice President of Operations & Cso |
| Richard J. Rodgers | Senior Vice President and CFO |
| Bruce J. Wendel | Executive. Vice President Corporate Development |
| Ed Geehr | Executive Vice President Operations |
| Marty Duvall | Senior Vice President, Global Marketing & Intl Commercial Operations |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Leon O. Moulder | Vice Chairman, President & CEO |
| David S. Chen | Board of Directors |
| Kirk K. Calhoun | Board of Directors |
| Leonard Shapiro | Board of Directors |
| Maili Bergman | Board of Directors |
| Patrick Soon-Shiong | Board of Directors |
| Stephen D. Nimer | Board of Directors |
| Steven Hassen | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Abraxis Biosciences, Inc. | Vice Chairman, President & CEO | Current |
| Abraxis Biosciences, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Abraxis Biosciences, Inc. | President and Chief Executive Officer | Current |
| Organization | Position | Status |
|---|---|---|
| Abraxis Biosciences, Inc. | Executive Vice President and Chief Financial Officer | Current |
David O'Toole joined Abraxis in 2008 with more than 24 years of experience in financial consulting and international tax services to global companies, and particular expertise in the life sciences industry. Before joining the team at Abraxis BioScience, Mr. O'Toole was with Deloitte & Touche LLP for 16 years, last serving as Partner - Strategic Client Group. There he was responsible for providing solutions to issues facing the life sciences industry, including enterprise cost reduction, commercialization and distribution of drugs, human resources, Sarbanes Oxley compliance and international tax planning. Mr. O'Toole was also Deloitte's Life Science leader in the Pacific Southwest for the last two years, helping to build their industry eminence in the marketplace. Mr. O'Toole's international experience includes a two year assignment in Paris, France, during which he was a consultant to large and medium-sized multi-national companies with an emphasis on cross border operational and tax planning. He also had a two year assignment in Tokyo, Japan. Mr. O'Toole earned his bachelor of science degree in accounting from the University of Arizona. He is a member of the American Institute of Certified Public Accountants, the California Society of Certified Public Accountants, the California Healthcare Institute and the Southern California Biomedical Counsel.
| Organization | Position | Status |
|---|---|---|
| Abraxis Biosciences, Inc. | CFO & Executive Vice President | Current |
| California Society of Certified Public Accountants | Board of Directors | Current |
| The University of Arizona | Bachelor of Science Degree In Accounting | Former |
| Organization | Position | Status |
|---|---|---|
| Abraxis Biosciences, Inc. | Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) | Current |
| Organization | Position | Status |
|---|---|---|
| Abraxis Biosciences, Inc. | Executive Vice President of Operations & Cso | Current |
| Organization | Position | Status |
|---|---|---|
| Abraxis Biosciences, Inc. | Senior Vice President and CFO | Current |
| Organization | Position | Status |
|---|---|---|
| Abraxis Biosciences, Inc. | Executive. Vice President Corporate Development | Current |
| American Bioscience Inc. | Executive Vice President, Corporate Development | Current |
| APP Pharmaceuticals, Inc. | Executive Vice President, Corp Dev | Current |
| Bristol-Myers Squibb Company | Vice President, Corporate Development International Medicines | Former |
| APP Pharmaceuticals, Inc. | Vice President of Corporate Development | Former |
| IVAX Corporation | Vice President, Business Development | Former |
| Bristol-Myers Squibb Company | In, House Counsel | Former |
| SmithKline Beecham Corporation | Former | |
| Georgetown University | Juris Doctorate degree | Former |
| Georgetown Law School | Jd | Former |
| Cornell University | BS | Former |
| Organization | Position | Status |
|---|---|---|
| Abraxis Biosciences, Inc. | Executive Vice President Operations | Current |
| Organization | Position | Status |
|---|---|---|
| Abraxis Biosciences, Inc. | Senior Vice President, Global Marketing & Intl Commercial Operations | Current |
David S. Chen, Ph.D. has served as a director since the separation in November 2007. Dr. Chen previously served as a director of Old Abraxis from June 1998 to the date of the separation. Dr. Chen has been a senior executive vice president of China Development Industrial Bank since February 2004. Dr. Chen also served as president of China Trust Venture Capital Corporation from October 2001 to May 2004 and was the chairman of Cypac Investment Management Limited from 1998-2001. He served as chief executive officer of Central Investment Holdings Company from July 1996 to February 2000, and chief financial officer from May 1991 to February 1994. Dr. Chen holds a B.S. in agricultural economics from National Taiwan University, a M.B.A. from California State University at Long Beach and a Ph.D. in business administration from Nova University, Florida.
| Organization | Position | Status |
|---|---|---|
| China Development Industrial Bank, Inc. | Senior Executive Vice President | Current |
| Abraxis Biosciences, Inc. | Board of Directors | Current |
| California State University | M.B.A. | Former |
| Organization | Position | Status |
|---|---|---|
| Cardiovascular Systems, Inc. | Chairman | Current |
| Adams Respiratory Therapeutics, Inc. | Chairman | Current |
| Aspreva Pharmaceuticals Corporation | Chairman | Current |
| Adams Laboratories, Inc. | Board of Directors | Current |
| Response Genetics | Board of Directors | Current |
| Abraxis Biosciences, Inc. | Board of Directors | Current |
| APP Pharmaceuticals, Inc. | Board of Directors | Current |
| Ernst & Young | partner | Former |
| Cardiovascular Systems, Inc. | Board of Directors | Former |
| Adams Respiratory Therapeutics, Inc. | Board of Directors | Former |
| Aspreva Pharmaceuticals Corporation | Board of Directors | Former |
| University of Southern California | B.S. in Accounting | Former |
| Organization | Position | Status |
|---|---|---|
| Shapco, Inc. | Founder | Current |
| Abraxis Biosciences, Inc. | Board of Directors | Current |
| Kelly Pipe Div. | President, Shapco | Former |
| Shapco, Inc. | CEO | Former |
| Shapco, Inc. | President | Former |
| Organization | Position | Status |
|---|---|---|
| Abraxis Biosciences, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| American College of Surgeons | Fellow | Current |
| APP Pharmaceuticals, Inc. | Board Chairman | Current |
| Abraxis Biosciences, Inc. | Board of Directors | Current |
| American College of Surgeons | Fellow | Current |
| APP Pharmaceuticals, Inc. | CEO | Former |
| Abraxis Biosciences, Inc. | Chairman and Chief Executive Officer | Former |
| American Bioscience Inc. | President | Former |
| American Bioscience Inc. | Cfo | Former |
| APP Pharmaceuticals, Inc. | Board Director | Former |
| American Bioscience Inc. | Board Director | Former |
| University of British Columbia | M.Sc | Former |
| University of the Witwatersrand | Degree | Former |
Dr. Nimer is Professor of Medicine and Professor of Pharmacology at Weill Medical College of Cornell University. He also serves as Chief of Hematology Service and Head of the Division of Hematologic Oncology at Memorial Sloan-Kettering Cancer Center in New York City. Dr. Nimer is a member of many national professional organizations, including the American Society of Hematology, the American Society of Clinical Oncology, and the International Society for Stem Cell Research. He serves as a Reviewer for major medical journals, including the New England Journal of Medicine and the Journal of the American Medical Association (JAMA) among many others. He serves on numerous national and international Grant Review Committees and is a prominent invited speaker at conferences on his areas of expertise. He has authored or co-authored nearly 200 peer-reviewed papers, reviews, editorials and textbook chapters, primarily focused on issues concerning hematology and oncology
| Organization | Position | Status |
|---|---|---|
| Memorial Sloan-Kettering Cancer Center Inc. | Chief of Hematology Service | Current |
| New England Journal of Medicine | Reviewer | Current |
| Memorial Hospital, Inc | Attending Physician | Current |
| The G&P Foundation for Cancer Research | Chairman | Current |
| Abraxis Biosciences, Inc. | Board of Directors | Current |
| American Society of Clinical Oncology | Board of Directors | Current |
| American Society of Hematology | Board of Directors | Current |
| Genpath | Board of Directors | Current |
| Neostem, Inc. | Board of Directors | Current |
| American Association for Cancer Research, Inc. | Board of Directors | Current |
| Onconova Therapeutics, Inc | Board of Directors | Current |
| APP Pharmaceuticals, Inc. | Board of Directors | Current |
| American Society of Hematology | Member | Current |
| American Association for Cancer Research, Inc. | Member | Current |
| American College of Physicians | Fellow | Current |
| Memorial Sloan-Kettering Cancer Center Inc. | Head | Former |
| University of California, Los Angeles | Former | |
| Cancer Research | Chairman | Former |
| University of Chicago | M.D. | Former |
| Massachusetts, Inc. | B.S. In Biology | Former |
| Massachusetts Institute of Technology | B.S. in Biology | Former |
| University of Chicago Pritzker School of Medicine | Degree | Former |
| Organization | Position | Status |
|---|---|---|
| Abraxis Biosciences, Inc. | Board of Directors | Current |
Industry Transcripts by Seeking Alpha
-
RadNet, Inc. Q3 2009 Earnings Call Transcript
on Nov 09, 2009about RDNT
-
Cytori Therapeutics Q3 2009 Earnings Call Transcript
on Nov 09, 2009about CYTX
-
StoneMor Partners L.P. 3Q09 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 09, 2009about STON
-
Sunrise Senior Living Inc Q3 2009 Earnings Call Transcript
on Nov 09, 2009about SRZ
-
Alphatec Holdings, Inc. Q3 2009 Earnings Call Transcript
on Nov 09, 2009about ATEC
IndustryTop Rated
- Why So Many Insured People Have Big Medical Debts 5 votes
- Physicians Know We Need Reform 4 votes
- Hospital Chain's Turnaround Raises Health Spending 3 votes
- Healthcare Is Still Adding Jobs, Despite Recession 3 votes
- Healthcare Roundup: Medical Office Space in Demand, Blues Companies See Lower Income, Two Sides of Health Insurance, and More 3 votes


